Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib in Cisplatin-Resistant Germ Cell Tumor
NCT02533765Phase 2Completed
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Sep 2015
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in germ cell tumor (GCT), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Started Sep 2015; status: completed.
02
Drugs
olaparib
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT02533765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02533765.